In our study, silencing TLR4 inhibited activation of the NLRP3 inflammasome and decreased expression of TGF-β, leading to reduction of atrial fibrosis and susceptibility to AF in vivo and CF proliferation in vitro. This evidence concerns the gene NLRP3 and cystic fibrosis.